Regulatory Lannett, Lanexa Biologics and Sunshine Lake secure FDA approval for Langlara Pharmaceutical Business ReviewLanglara is cleared for use in adults and children with type 1 diabetes mellitus (T1DM), as well as adults with type 2 diabetes mellitus (T2DM).Read full story pharminent May 5, 2026 (Last updated: May 5, 2026) Pharmaceutical Business Review Langlara is cleared for use in adults and children with type 1 diabetes mellitus (T1DM), as well as adults with type 2 diabetes mellitus (T2DM). Read full story Post navigation Previous: ‘Seismic shift’ as obesity overtakes cancer for R&D returnsNext: Specialty Pharmacy Accreditation: DCI’s Exclusive Analysis Reveals a Market at an Inflection Point Related Stories Regulatory Scholar Rock’s muscle-targeting SMA therapy Isemblyd lands FDA approval pharminent September 14, 2026 Regulatory Psychedelic therapies ride wave of public favor into FDA hearing pharminent September 14, 2026 Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026